The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Inhaled and Intranasal Products Contract Service Providers Market by Product Manufacturing Services (API Manufacturing, End Product Manufacturing and Others), Drug Delivery System (Metered Dose Inhaler, Dry Powder Inhaler, Nebulizer and Nasal Spray), Route of Administration (Orally Inhaled and Intranasal), Scale of Operation (Clinical, Commercial and Both) and Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    September 2020

  • Pages
    223

  • View Count
    1658

Example Insights

Inhaled-and-Intranasal-Products-Context 	Inhaled-and-Intranasal-Products-List-of-Service-Providers Inhaled-and-Intranasal-Products-Inhaled-and-Intranasal-Drug-Product
Inhaled-and-Intranasal-Products-Geographical-Distribution Inhaled-and-Intranasal-Products-Manufacturing-Service-Providers Inhaled-and-Intranasal-Products-Competitiveness-Analysis
Inhaled-and-Intranasal-Products-Partnerships-and-Collaborations Inhaled-and-Intranasal-Products-Global-Demand Inhaled-and-Intranasal-Products-Market-Forcast

 

Overview

Over the past few decades, the prevalence of respiratory disorders has been increasing at an alarming rate. In fact, each year around 7 million deaths are attributed to respiratory disorders caused by air pollution, worldwide.Moreover, as per a Global Burden of Disease study, around 3 million fatalities are reported annually due to chronic obstructive pulmonary disorders (COPD). It is also important to note that, as of April 2020, an estimated 330 million individuals are suffering from asthma.Other causative factors responsible for respiratory diseases include smoking, climate change, low immunity, inappropriate development of lungs, and bacterial, viral and fungal infections.It is worth mentioning that the novel SARS-CoV2 viral strain is a respiratory pathogen.  

Targeting the delivery of drugs directly into the lungs is deemed to be the most effective way to ensure optimal therapeutic benefits while treating pulmonary disorders. In addition, this route of administration has also been shown to be effective for drugs intended to treat a variety of other conditions, including various metabolic (460+ million adults estimated to be living with diabetes) , hormonal, autoimmune, infectious diseases / disorders and mental health conditions (260 million individuals estimated to be suffering from depression and around 50 million have epilepsy, worldwide). As a result, innovators in the pharmaceutical industry are engaged in efforts to develop the means to formulate and administer pharmacological interventions via inhalation and / or the intranasal route. Since 2019, the FDA has approved multiple inhaled and intranasal drug products, namely TOSYMRA™ (migraine), NUMBRINO™ (local anesthetic), GIMOTI™ (diabetic gastroparesis), VALTOCO® (epilepsy), NAYZILAM® (epilepsy), DUAKLIR® PRESSAIR® (COPD), PROAIR® DIGIHALER™ (asthma and COPD), AIRDUO® DIGIHALER™ (asthma), SPRAVATO® (depression). 

Presently, several players are attempting to develop inhalable versions of different classes of drugs. In such endeavors, reformulating complex therapeutic molecules (such as biologics), novel drug classes (such as nanoparticle based medicine) and those intended for systemic delivery, present unique challenges.Further, the inhaled route of delivery itself has always been associated with several challenges, mostly related to ensuring the drug to its intended target. These concerns are further compounded by multiple physiological barriers, such as mucus hypersecretion / thickening, narrowing / collapse of airways, fibrosis and poor blood circulation. In order to navigate through the aforementioned challenges, innovators prefer to rely on specialty service providers with expertise in inhaled and intranasal nasal medicine. Such players, given their experience and niche expertise, enable innovator companies to not only expedite product development and production timelines, but also offer cost saving opportunities as well. Further, such service providers generally have the necessary infrastructure to scale-up operations in order to meet the evolving needs of a business across different stages of product development. Given the anticipated growth in demand for inhaled and intranasal drug products, the specialty contract services market catering to this segment of the pharmaceutical industry, is anticipated to witness substantial growth in the coming years.

Scope of the Report

The ‘Inhaled and Intranasal Products: Contract Service Providers Market (Focus on Drugs and Drug Delivery Systems), 2020 – 2030’ report features an extensive study of the current market landscape and future opportunities for the contract service providers focused on drugs and drug delivery systems. It features an in-depth analysis, highlighting the capabilities of various contract service providers engaged in this domain. Amongst other elements, the report includes:

  • A detailed assessment of the overall landscape of companies offering contract and custom services for the inhaled and Intranasal drug development and manufacturing, along with information on a number of relevant parameters, such as year of establishment, company size, type of service provider (contract manufacturing organization and contract research organization), scale of operation (preclinical, clinical and commercial), location of headquarters, location of manufacturing facilities, type of drug molecule (small molecule and biologic), type of inhaled and intranasal related primary service(s) offered (development, manufacturing, analytical testing / services, device selection / optimization and fill / finish and packaging), type of inhaled and intranasal related secondary service(s) offered (process development, pre-formulation development, formulation development, pre-formulation manufacturing, formulation manufacturing, particle engineering, product characterization, extractable and leachable studies, stability testing and plume geometry measurement), type of formulation (powder, aerosol and liquid), type of dosage form (metered dose inhaler, dry powder inhaler, nebulizer, soft mist inhaler, nasal spray, nasal drops, nasal powder and others), route of administration (oral and intranasal inhalation) and installed capacity and batch size (if available).
  • A detailed assessment of the overall landscape of the companies offering contract services for the inhaled and intranasal drug delivery system manufacturing, along with information on a number of relevant parameters, such as year of establishment, company size, scale of operation (precommercial and commercial), location of headquarters, location of manufacturing facilities, type of inhaled and intranasal drug delivery system related service(s) offered (design, development, manufacturing, assembly, fill / finish and packaging), type of formulation (powder, aerosol and liquid) and type of drug delivery system used (metered dose inhaler, dry powder inhaler, nebulizer, nasal spray and others).
  • A competitiveness analysis of inhaled and intranasal drug product contract service providers across key geographical areas, featuring a four-dimensional bubble representation, taking into consideration service strength (number of services offered, type of formulation(s) offered and route of administration), manufacturing strength (type of drug molecule, scale of operation, number of manufacturing facilities), supplier strength (company size and its experience in this field) and company size (small-sized, mid-sized and large).
  • Tabulated profiles of some of the key contract manufacturers (shortlisted based on a proprietary criterion) that offer a diverse range of capabilities for the development, manufacturing and packaging of inhaled and intranasal drugs across North America, Europe and Asia-Pacific. Each profile features an overview of the company, along with information related to its financial performance (if available), service portfolio, products and intranasal related capabilities, type of drug molecule, type of dosage form, inhaled and intranasal products related manufacturing facilities, recent developments and an informed future outlook.
  • An analysis of the various partnerships related to inhaled and intranasal contract service providers, which have been established since 2015, based on several parameters, such as year of agreement, type of partnership (development agreements, manufacturing agreements, merger and acquisition, licensing agreement, commercialization, research and development agreements, service alliance, joint venture and other agreements), scale of operation (preclinical, clinical and commercial), type of inhaled and intranasal related service(s) offered (development, manufacturing, analytical testing / services and fill / finish and packaging), type of dosage form (metered dose inhalers, dry powder inhalers, nebulizers and others) and most active players. It also provides the regional distribution of the players involved in the collaborations.
  • A qualitative analysis highlighting the various factors that need to be taken into consideration by inhaled and intranasal product developers, while deciding whether to manufacture their respective products in-house or engage a contract service provider.
  • An estimate of the global, inhaled and intranasal product demand, based on the type of product (inhaled and intranasal), type of drug delivery system used (metered dose inhalers, dry powder inhalers, nebulizers and nasal sprays) and key geographical regions (North America, Europe and Asia-Pacific).
  • An insightful discussion on the impact of COVID-19 outbreak on the inhaled and intranasal service providers. In addition, it features various strategies that different companies have adopted / may adopt in order to mitigate the challenges affiliated to the current global crisis.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as overall pulmonary market, global intranasal drug market, cost of goods sold and outsourcing trends, we have provided an informed estimate of the likely evolution of the contract service providers market in the mid to long term, for the time period 2020-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] scale of operation (clinical, commercial and both), [B] type of product manufacturing services offered (API manufacturing, end product manufacturing and others), [C] type of drug delivery system used (metered dose inhaler, dry powder inhaler, nebulizer and nasal spray), [D] route of administration (orally inhaled and intranasal) and [E] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In addition, specific to intranasal service providers, the market has been segmented by the type of drug class (corticosteroids, decongestants, antiallergic, anti-infectives and other topical preparations) and for inhalation service providers, the market has been segmented by the type of disease indication (asthma, COPD, diabetes, cystic fibrosis and others).  In addition to the market forecast for inhaled and intranasal drugs, we have also provided a 10-year forecast for inhaled and intranasal drug delivery systems, covering the market of metered dose inhaler, dry powder inhaler, nebulizer and nasal spray. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry and non-industry players:

  • Ben Forbes (Professor, King’s College London)
  • Dries Cardoen (Team Leader of Study Directors, Nelson Laboratories)
  • Neeraj Kumar (Honorary Secretary, The Indian Pharmaceutical Association)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading contract service providers offering inhalable and intranasal products related services, across the world?
  • In which regions are majority of the inhaled and intranasal product related manufacturing facilities located?
  • What percentage of inhaled and intranasal manufacturing operations are outsourced?
  • Which partnership models are commonly adopted by stakeholders in this industry?
  • What is the impact of COVID-19 outbreak on inhaled and intranasal product services market?
  • What is the current, global demand for inhaled and intranasal products?
  • How is the current and future market opportunity likely to be distributed across key market segments?
     

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the current state of inhaled and intranasal service providers market and its likely evolution in the short to mid-term and long term.

Chapter 3 provides a general introduction to inhaled and intranasal related drugs and drug delivery systems. The chapter also includes the historical evolution of inhaled and intranasal therapy. It features a brief overview of the type of inhalable and intranasal drug formulations, type of inhaled and intranasal drugs and delivery systems, assessment of quality and performance during inhaled and intranasal development, regulatory landscape, approved inhaled and intranasal products and importance of outsourcing in this domain. Further, the chapter also discusses the future perspective of the inhaled and intranasal service providers market.

Chapter 4 includes a detailed analysis of the current market landscape of over 110 drug based contract service providers, based on year of establishment, company size, type of service provider (contract manufacturing organization and contract research organization), scale of operation (preclinical, clinical and commercial), location of headquarters, location of manufacturing facilities, type of drug molecule (small molecule and biologic), type of inhaled and intranasal related primary service(s) offered (development, manufacturing, analytical testing / services, device selection / optimization and fill / finish and packaging), type of inhaled and intranasal related secondary service(s) offered (process development, pre-formulation development, formulation development, particle engineering, product characterization, extractable and leachable studies, stability testing and plume geometry measurement), type of formulation (powder, aerosol and liquid), type of dosage form (metered dose inhaler, dry powder inhaler, nebulizer, soft mist inhaler, nasal spray, nasal drops, nasal powder and others), route of administration (oral and nasal inhalation) and installed capacity and batch size (if available).

Chapter 5 includes a detailed includes a detailed analysis of the current market landscape of around 20 drug delivery system based contract manufacturers, year of establishment, company size, scale of operation (precommercial and commercial), location of headquarters, location of manufacturing facilities, type of inhaled and intranasal drug delivery system related service(s) offered (design, development, manufacturing, assembly, fill / finish and packaging), type of formulation (powder, aerosol and liquid) and type of drug delivery system used (metered dose inhaler, dry powder inhaler, nebulizer, nasal spray and others).

Chapter 6 presents a detailed competitiveness analysis of inhaled and intranasal products providers across the type of service providers and key geographical areas. It features a four-dimensional bubble representation, taking into consideration service strength (number of services offered, type of formulation(s) offered and route of administration), manufacturing strength (type of drug molecule, scale of operation, number of manufacturing facilities), supplier strength (company size and its experience in this field) and company size (small-sized, mid-sized and large).

Chapter 7 features tabulated profiles of some of the key contract manufacturers that are active in the inhaled and intranasal service providers market in North America. Each profile presents a brief overview of the company, along with information related to its financial information (if available), service portfolio, inhaled and intranasal related capabilities, type of drug molecule(s), type of dosage form(s), inhaled and intranasal products related manufacturing facilities and recent developments and an informed future outlook.

Chapter 8 features tabulated profiles of some of the key contract manufacturers that are active in the inhaled and intranasal service providers market in Europe and Asia-Pacific. Each profile presents a brief overview of the company, along with information related to its financial information (if available), service portfolio, inhaled and intranasal related capabilities, type of drug molecule(s), type of dosage form(s), inhaled and intranasal products related manufacturing facilities and recent developments and an informed future outlook.

Chapter 9 features in-depth analysis and discussion of the various partnerships inked between the players in this market, during the period, 2015-2020, covering analysis based on parameters such as year of agreement, type of partnership (development agreements, manufacturing agreements, merger and acquisition, licensing agreement, commercialization, research and development agreements, service alliance, joint venture and other agreements), scale of operation (preclinical, clinical and commercial), type of inhaled and intranasal related service(s) offered (development, manufacturing, analytical testing / services and fill / finish and packaging), type of dosage form (metered dose inhalers, dry powder inhalers, nebulizers and others) and most active players. It also provides the regional distribution of the players involved in the collaborations.

Chapter 10 presents a qualitative analysis that highlights the various factors that need to be taken into consideration by inhaled and intranasal product developers, while deciding whether to manufacture their respective products in-house or engage the services of a contract service organization.

Chapter 11 provides an overview of the demand for inhaled and intranasal products. The study examines the distribution of demand, based on the route of administration (orally inhaled and intranasal), type of drug delivery system used (metered dose inhalers, dry powder inhalers, nebulizers and nasal sprays) and key geographical areas (North America, Europe and Asia-Pacific).

Chapter 12 presents a comprehensive market forecast analysis, highlighting the likely growth of the inhaled and intranasal product service providers market, for the time period 2020-2030. In order to provide an informed future outlook, our projections have been segmented on the basis of [A] scale of operation (clinical, commercial and both), [B] type of product manufacturing services offered (API manufacturing, end product manufacturing and others), [C] type of drug delivery system used (metered dose inhaler, dry powder inhaler, nebulizer and nasal spray), [D] route of administration (orally inhaled and intranasal) and [E] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In addition, specific to intranasal service providers the market has been segmented by the type of drug class (corticosteroids, decongestants, antiallergic, anti-infectives and other topical preparations) and for inhalation service providers the segmentation has been done by the type of disease indication (asthma, COPD, diabetes, cystic fibrosis, other).  In addition to the market forecast for inhaled and intranasal drugs, we have also provided a 10-year forecast for inhaled and intranasal drug delivery systems, covering the market of metered dose inhaler, dry powder inhaler, nebulizer and nasal spray.

Chapter 13 highlights the effect of coronavirus outbreak on the inhaled and intranasal service providers market. It includes a brief discussion on the short-term and long-term impact of COVID-19 on the supply chain and market opportunity for drug developers and contract service providers. In addition, it includes a brief section on strategies and action plans that pharma companies are likely to adopt in order to prepare for supply chain disruptions in future.

Chapter 14 summarizes the overall report. wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the inhaled and intranasal service providers market.

Chapter 15 is a collection of transcripts of interviews conducted with key stakeholders in the industry. In this chapter, we have presented the details of our conversations with Ben Forbes (Professor, King’s College London), Dries Cardoen (Team Leader of Study Directors, Nelson Laboratories) and Neeraj Kumar (Honorary Secretary, The Indian Pharmaceutical Association).

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 17 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents 

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Historical Evolution of Inhaled and Intranasal Therapy 
3.3. Types of Inhalable and Intranasal Drug Formulations

3.4. Types of Inhalable and Intranasal Drug Delivery Systems Formulations 
3.4.1. Pressurized Metered Dose Inhalers
3.4.2. Dry Powder Inhalers
3.4.3. Nebulizers
3.4.4. Metered Spray Pumps / Intranasal Sprays 
3.4.5. Aqueous Droplet Inhalers 

3.5. Assessment of Quality and Performance During Inhalable and Intranasal Drug Development
3.6. Regulatory Landscape
3.7. Approved Inhaled and Intranasal Therapeutics Available in Developed Markets (the US and UK)
3.8. Importance of Outsourcing Inhaled and v Product Development Operations
3.9. Future Perspectives

4. INHALED AND INTRANASAL DRUG PRODUCT SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Inhaled and Intranasal Drug Product Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Logo Landscape: Analysis by Year of Establishment and Company Size
4.2.4. Analysis by Type of Service Provider 

4.2.5. Analysis by Company Size and Type of Service Provider
4.2.6. Analysis by Scale of Operation
4.2.7. Analysis by Location of Headquarters
4.2.8. Heat Map: Analysis by Company Size and Location of Headquarters
4.2.9. World Map: Analysis by Inhaled and Intranasal Drug Product Manufacturing Facilities
4.2.10. Analysis by Type of Drug Molecule
4.2.11. Analysis by Type of Inhaled and Intranasal Drug Product Related Primary Service(s) Offered
4.2.12. Analysis by Type of Inhaled and Intranasal Drug Product Related Secondary Service(s) Offered
4.2.13. Analysis by Type of Formulation
4.2.14. Analysis by Type of Dosage Form 
4.2.15. Analysis by Route of Administration 
4.2.16. Information on Production Capacity 

5. INHALED AND INTRANASAL DRUG DELIVERY SYSTEM MANUFACTURING SERVICE PROVIDERS: MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Logo Landscape: Analysis by Year of Establishment and Company Size  
5.2.4. Analysis by Scale of Operation
5.2.5. Analysis by Location of Headquarters
5.2.6. Analysis by Location of Inhaled and Intranasal Drug Delivery System Manufacturing Facilities
5.2.7. Analysis by Type of Inhaled and Intranasal Drug Delivery System Manufacturing Service(s) Offered
5.2.8. Analysis by Type of Formulation
5.2.10. Analysis by Type of Drug Delivery Systems

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology and Key Parameters
6.3. Inhaled and Intranasal Drug Product Contract Manufacturing Service Providers
6.3.1. Inhaled and Intranasal Drug Product Contract Manufacturing Service Providers based in North America
6.3.2. Inhaled and Intranasal Drug Product Contract Manufacturing Service Providers based in Europe
6.3.3. Inhaled and Intranasal Drug Product Contract Manufacturing Service Providers based in Asia-Pacific and Rest of the World
6.4. Inhaled and Intranasal Drug Product Contract Research Service Providers
6.4.1. Inhaled and Intranasal Drug Product Contract Research Service Providers based in North America
6.4.2. Inhaled and Intranasal Drug Product Contract Research Service Providers based in Europe
6.4.3. Inhaled and Intranasal Drug Product Contract Research Service Providers based in Asia-Pacific and Rest of the World
6.5. Inhaled and Intranasal Drug Product Contract Research and Manufacturing Service Providers
6.5.1. Inhaled and Intranasal Drug Product Contract Research and Manufacturing Service Providers based in North America
6.5.2. Inhaled and Intranasal Drug Product Contract Research and Manufacturing Service Providers based in Europe
6.5.3. Inhaled and Intranasal Drug Product Contract Research and Manufacturing Service Providers based in Asia-Pacific and Rest of the World

7. INHALED AND INTRANASAL CONTRACT MANUFACTURING SERVICE PROVIDERS IN NORTH AMERICA
7.1. Chapter Overview
7.2. Capsugel
7.2.1. Recent Developments and Future Outlook

7.3. Catalent
7.3.1. Recent Developments and Future Outlook

7.4. DPT Laboratories (A Mylan Company)
7.4.1. Recent Developments and Future Outlook

7.5. Kindeva Drug Delivery (Formerly 3M Drug Delivery Systems) 
7.5.1. Recent Developments and Future Outlook

8. INHALED AND INTRANASAL CONTRACT MANUFACTURING SERVICE PROVIDERS IN EUROPE AND ASIA-PACIFIC
8.1. Chapter Overview
8.2. Beximco Pharmaceuticals
8.2.1. Recent Developments and Future Outlook 

8.3. Colep
8.3.1. Recent Developments and Future Outlook

8.4. Hovione
8.4.1. Recent Developments and Future Outlook

8.5. Orion
8.5.1. Recent Developments and Future Outlook

8.6. Quotient Sciences
8.6.1. Recent Developments and Future Outlook

8.7. Recipharm
8.7.1. Recent Developments and Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Inhaled and Intranasal Contract Research and Manufacturing Service Providers: 
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Scale of Operation
9.3.4. Analysis by Type of Inhaled and Intranasal Drug Product Related Service(s) Offered
9.3.5. Analysis by Type of Formulation
9.3.6. Analysis by Type of Drug Delivery Systems Used
9.3.7. Most Active Players: Analysis by Number of Partnerships

9.3.8. Geographical Analysis
9.3.8.1. Intercontinental and Intracontinental Agreements

10. MAKE VERSUS BUY DECISION MAKING
10.1. Chapter Overview
10.2. Assumptions and Parameter Definitions
10.2.1. Scenario 1
10.2.2. Scenario 2
10.2.3. Scenario 3
10.2.4. Scenario 4
10.3. Concluding Remarks

11. DEMAND ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodology
11.3. Global Demand for Inhaled and Intranasal Drug Delivery Systems, 2020-2030
11.3.1. Analysis by Route of Administration
11.3.2. Analysis by Type of Drug Delivery Systems Used
11.3.3. Analysis by Geographical Location

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Overall Inhaled and Intranasal Drug Product Contract Manufacturing Market, 2020-2030
12.3.1. Inhaled and Intranasal Drug Product Contract Manufacturing Market: Distribution by Scale of Operation, 2020-2030
12.3.2. Inhaled and Intranasal Drug Product Contract Manufacturing Market: Distribution by Type of Inhaled and Intranasal Drug Product Related Service, 2020-2030
12.3.3. Inhaled and Intranasal Drug Product Contract Manufacturing Market: Distribution by Type of Drug Delivery Systems Used, 2020-2030
12.3.4. Inhaled and Intranasal Drug Product Contract Manufacturing Market: Distribution by Route of Administration, 2020-2030
12.3.5. Inhaled and Intranasal Drug Product Contract Manufacturing Market: Distribution by Key Geographical Regions, 2020-2030

12.4. Inhaled and Intranasal Drug Product Contract Manufacturing Market for Inhalable Formulations, 2020-2030
12.4.1. Inhaled and Intranasal Drug Product Contract Manufacturing Market for Inhalable Formulations: Distribution by Type of Disease Indication, 2020-2030

12.5. Inhaled and Intranasal Drug Product Contract Manufacturing Market for Nasal Formulations, 2020-2030
12.5.1. Inhaled and Intranasal Drug Product Contract Manufacturing Market for Nasal Formulations: Distribution by Type of Drug Class, 2020-2030

12.6. Overall Inhaled and Intranasal Drug Delivery System Contract Manufacturing Market, 2020-2030
12.6.1. Inhaled and Intranasal Drug Delivery System Contract Manufacturing Market: Distribution by Type of Drug Delivery System Used, 2020-2030
12.6.2. Inhaled and Intranasal Drug Delivery System Contract Manufacturing Market: Distribution by Route of Administration, 2020-2030
12.6.3. Inhaled and Intranasal Drug Delivery System Contract Manufacturing Market: Distribution by Key Geographical Regions, 2020-2030

13. IMPACT OF COVID-19 PANDEMIC ON THE INHALED AND INTRANASAL SERVICE PROVIDERS MARKET
13.1 Chapter Overview
13.2. Current Opinions and Recuperative Initiatives of Key Players
13.2.1. Catalent
13.2.2. Hovione
13.2.3. Lonza
13.2.4. Quotient Sciences
13.2.5. Recipharm

13.3. Impact on Inhaled and Intranasal Product Service Providers Market
13.4. Recuperative Strategies for Contract Service Providers
13.4.1. Strategies for Implementation in the Short / Mid Term
13.4.2. Strategies for Implementation in the Long Term

14. CONCLUSION
14.1. Chapter Overview

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. King’s College London
15.2.1. Organization Snapshot
15.2.2. Interview Transcript: Ben Forbes, Professor

15.3. Nelson Laboratories
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Dries Cardoen, Team Leader of Study Directors

15.4. The Indian Pharmaceutical Association
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Neeraj Kumar, Honorary Secretary

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Types of Inhalable and Intranasal Drug Formulations
Figure 3.2 Inhaled and Intranasal Product Development: Quality and Performance Assessment
Figure 3.3 Inhaled and Intranasal Product Development: Type of Outsourcing
Figure 4.1 Inhaled and Intranasal Drug Product Service Providers: Distribution by Year of Establishment
Figure 4.2 Inhaled and Intranasal Drug Product Service Providers: Distribution by Company Size
Figure 4.3 Logo Landscape: Distribution by Year of Establishment and Company Size
Figure 4.4 Inhaled and Intranasal Drug Product Service Providers: Distribution by Type of Service Provider
Figure 4.5 Inhaled and Intranasal Drug Product Service Providers: Distribution by Company Size and Type of Service Provider
Figure 4.6 Inhaled and Intranasal Drug Product Service Providers: Distribution by Scale of Operation
Figure 4.7 Inhaled and Intranasal Drug Product Service Providers: Distribution by Location of Headquarters
Figure 4.8 World Map: Distribution by Inhaled and Intranasal Drug Product Manufacturing Facilities
Figure 4.9 Inhaled and Intranasal Drug Product Service Providers: Distribution by Type of Drug Molecule
Figure 4.10 Inhaled and Intranasal Drug Product Service Providers: Distribution by Inhaled and Intranasal Drug Product Related Primary Service(s) Offered
Figure 4.11 Inhaled and Intranasal Drug Product Service Providers: Distribution by Inhaled and Intranasal Drug Product Related Secondary Service(s) Offered
Figure 4.12 Inhaled and Intranasal Drug Product Service Providers: Distribution by Type of Formulation
Figure 4.13 Inhaled and Intranasal Drug Product Service Providers: Distribution by Type of Dosage Form
Figure 4.14 Inhaled and Intranasal Drug Product Service Providers: Distribution by Route of Administration
Figure 5.1 Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers: Distribution by Year of Establishment
Figure 5.2 Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers: Distribution by Company Size
Figure 5.3 Logo Landscape: Distribution by Year of Establishment and Company Size
Figure 5.4 Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers: Distribution by Scale of Operation
Figure 5.5 Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers: Distribution by Location of Headquarters
Figure 5.6 Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers: Distribution by Location of Inhaled and Intranasal Drug Delivery System Manufacturing Facilities
Figure 5.7 Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers: Distribution by Type of Inhaled and Intranasal Drug Delivery System Manufacturing Service(s) Offered
Figure 5.8 Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers: Distribution by Type of Formulation
Figure 5.9 Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers: Distribution by Type of Drug Delivery System Used
Figure 6.1 Company Competitiveness Analysis: Inhaled and Intranasal Drug Product Contract Manufacturing Service Providers based in North America
Figure 6.2 Company Competitiveness Analysis: Inhaled and Intranasal Drug Product Contract Manufacturing Service Providers based in Europe
Figure 6.3 Company Competitiveness Analysis: Inhaled and Intranasal Drug Product Contract Manufacturing Service Providers based in Asia-Pacific
Figure 6.4 Company Competitiveness Analysis: Inhaled and Intranasal Drug Product Contract Research Service Providers based in North America
Figure 6.5 Company Competitiveness Analysis: Inhaled and Intranasal Drug Product Contract Research Service Providers based in Europe
Figure 6.6 Company Competitiveness Analysis: Inhaled and Intranasal Drug Product Contract Research Service Providers based in Asia-Pacific
Figure 6.7 Company Competitiveness Analysis: Inhaled and Intranasal Drug Product Contract Research and Manufacturing Service Providers based in North America
Figure 6.8 Company Competitiveness Analysis: Inhaled and Intranasal Drug Product Contract Research and Manufacturing Service Providers based in Europe
Figure 6.9 Company Competitiveness Analysis: Inhaled and Intranasal Drug Product Contract Research and Manufacturing Service Providers based in Asia-Pacific
Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-June 2020
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership, 2015-June 2020
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partnership, 2015-2017 and 2018-June 2020
Figure 9.5 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 9.6 Partnerships and Collaborations: Distribution by Type of Inhaled and Intranasal Drug Product Related Service(s) Offered
Figure 9.7 Partnerships and Collaborations: Distribution Type of Formulation
Figure 9.8 Partnerships and Collaborations: Distribution by Type of Drug Delivery System Used
Figure 9.9 Most Active Players: Distribution by Number of Partnerships
Figure 9.10 Partnerships and Collaborations: Geographical Analysis
Figure 9.11 Partnerships and Collaborations: Intercontinental and Intracontinental
Figure 10.1 Make versus Buy Decision Making Framework
Figure 11.1 Global Demand for Inhaled and Intranasal Drug Delivery Systems, 2020-2030 (Million Units)
Figure 11.2 Global Demand for Inhaled and Intranasal Drug Delivery Systems: Distribution by Route of Administration, 2020-2030 (Million Units)
Figure 11.3 Global Demand for Inhaled and Intranasal Drug Delivery Systems: Distribution by Type of Drug Delivery System Used, 2020-2030 (Million Units)
Figure 11.4 Global Demand for Inhaled and Intranasal Drug Delivery Systems: Distribution by Key Geographical Location, 2020-2030 (Million Units)
Figure 12.1 Overall Inhaled and Intranasal Drug Product Contract Manufacturing Market, 2020-2030 (USD Billion)
Figure 12.2 Inhaled and Intranasal Drug Product Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation (USD Million)
Figure 12.3 Inhaled and Intranasal Drug Product Contract Manufacturing Market, 2020-2030: Distribution by Type of Inhaled and Intranasal Drug Product Related Service(s) (USD Million)
Figure 12.4 Inhaled and Intranasal Drug Product Contract Manufacturing Market, 2020-2030: Distribution by Type of Drug Delivery System Used (USD Million)
Figure 12.5 Inhaled and Intranasal Drug Product Contract Manufacturing Market, 2020-2030: Distribution by Route of Administration (USD Million)
Figure 12.6 Inhaled and Intranasal Drug Product Contract Manufacturing Market, 2020-2030: Distribution by Key Geographical Regions (USD Million)
Figure 12.7 Inhaled and Intranasal Drug Product Contract Manufacturing Market for Inhalable Formulations, 2020-2030: Distribution by Type of Therapeutics Area (USD Million)
Figure 12.8 Inhaled and Intranasal Drug Product Contract Manufacturing Market for Nasal Formulations, 2020-2030: Distribution by Type of Drug Class (USD Million)
Figure 12.9 Overall Inhaled and Intranasal Drug Delivery System Contract Manufacturing Market, 2020-2030 (USD Billion)
Figure 12.10 Inhaled and Intranasal Drug Delivery System Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation (USD Million)
Figure 12.11 Inhaled and Intranasal Drug Delivery System Contract Manufacturing Market, 2020-2030: Distribution by Type of Drug Delivery System Used (USD Million)
Figure 12.12 Inhaled and Intranasal Drug Delivery System Contract Manufacturing Market, 2020-2030: Distribution by Route of Administration (USD Million)
Figure 12.13 Inhaled and Intranasal Drug Delivery System Contract Manufacturing Services Market, 2020-2030: Distribution by Key Geographical Regions (USD Million)
Figure 13.1 Inhaled and Intranasal Product Contract Services Market, 2015-2030: COVID-19 Impact Informed Scenario (USD Billion)
Figure 14.1 Concluding Remarks: Current Inhaled and Intranasal Drug Product Service Providers Market Landscape Summary
Figure 14.2 Concluding Remarks: Current Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers Market Landscape Summary
Figure 14.3 Concluding Remarks: Partnerships and Collaborations
Figure 14.4 Concluding Remarks: Demand Analysis
Figure 14.5 Concluding Remarks: Market Sizing and Opportunity Analysis for Drug Product Contract Manufacturing Market
Figure 14.6 Concluding Remarks: Market Sizing and Opportunity Analysis for Drug Delivery System Contract Manufacturing Market

List Of Tables

Table 3.1 List of Approved Products: Pressurized Metered Dose Inhalers
Table 3.2 List of Approved Products: Dry Powder Inhalers
Table 3.3 List of Approved Products: Nebulizers
Table 3.4 Inhaled and Intranasal Products: Guidelines by the FDA and the EMA
Table 4.1 List of Inhaled and Intranasal Drug Product Service Providers
Table 4.2 Inhaled and Intranasal Drug Product Service Providers: Information on Company Size and Location of Headquarters
Table 4.3 Inhaled and Intranasal Drug Product Service Providers: Information on Location and Number of Inhaled and Intranasal Drug Product Manufacturing Facilities
Table 4.4 Inhaled and Intranasal Drug Product Service Providers: Information on Type of Drug Molecule
Table 4.5 Inhaled and Intranasal Drug Product Service Providers: Information on Inhaled and Intranasal Drug Product Related Service(s) Offered
Table 4.6 Inhaled and Intranasal Drug Product Service Providers: Information on Type of Formulation
Table 4.7 Inhaled and Intranasal Drug Product Service Providers: Information on Type of Dosage Form
Table 4.8 Inhaled and Intranasal Drug Product Service Providers: Information on Route of Administration
Table 4.9 Inhaled and Intranasal Drug Product Service Providers: Information on Production Capacity
Table 5.1 List of Inhaled and Intranasal Drug Delivery System Drug Delivery System Manufacturing Service Providers
Table 5.2 Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers: Information on Location and Number of Inhaled and Intranasal Drug Delivery System Manufacturing Facilities
Table 5.3 Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers: Information on Type of Inhaled and Intranasal Drug Delivery System Manufacturing Service(s) Offered
Table 5.4 Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers: Information on Type of Formulation
Table 5.5 Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers: Information on Type of Drug Delivery System Used
Table 7.1 Capsugel: Company Snapshot
Table 7.2 Capsugel: Recent Developments and Future Outlook
Table 7.3 Catalent: Company Snapshot
Table 7.4 Catalent: Recent Developments and Future Outlook
Table 7.5 DPT Laboratories: Company Snapshot
Table 7.6 DPT Laboratories: Recent Developments and Future Outlook
Table 7.7 Kindeva Drug Delivery: Company Snapshot
Table 7.8 Kindeva Drug Delivery: Recent Developments and Future Outlook
Table 8.1 Beximco Pharmaceuticals: Company Snapshot
Table 8.2 Beximco Pharmaceuticals: Recent Developments and Future Outlook
Table 8.3 Colep: Company Snapshot
Table 8.4 Colep: Recent Developments and Future Outlook
Table 8.5 Hovione: Company Snapshot
Table 8.6 Hovione: Recent Developments and Future Outlook
Table 8.7 Orion: Company Snapshot
Table 8.8 Orion: Recent Developments and Future Outlook
Table 8.9 Quotient Sciences: Company Snapshot
Table 8.10 Quotient Sciences: Recent Developments and Future Outlook
Table 8.11 Recipharm: Company Snapshot
Table 8.12 Recipharm: Recent Developments and Future Outlook
Table 9.1 Inhaled and Intranasal Contract Research and Manufacturing Service Providers: List of Partnerships and Collaborations, 2015-2020
Table 9.2 Inhaled and Intranasal Contract Research and Manufacturing Service Providers: Information on Scale of Production and Inhaled and Intranasal Drug Product Related Services(s) Offered, 2015-2020
Table 9.3 Inhaled and Intranasal Contract Research and Manufacturing Service Providers: Information on Type of Formulation, Type of Drug Delivery System Used and Route of Administration, 2015-2020
Table 15.1 King’s College London: Key Highlights
Table 15.2 Nelson Laboratories: Key Highlights
Table 15.3 The Indian Pharmaceutical Association: Key Highlights
Table 16.1 Inhaled and Intranasal Drug Product Service Providers: Distribution by Year of Establishment
Table 16.2 Inhaled and Intranasal Drug Product Service Providers: Distribution by Company Size
Table 16.3 Inhaled and Intranasal Drug Product Service Providers: Distribution by Company Size and Type of Service Provider
Table 16.4 Inhaled and Intranasal Drug Product Service Providers: Distribution by Scale of Operation
Table 16.5 Inhaled and Intranasal Drug Product Service Providers: Distribution by Location of Headquarters
Table 16.6 Inhaled and Intranasal Drug Product Service Providers: Distribution by Location of Inhaled and Intranasal Drug Product Manufacturing Facilities
Table 16.7 Inhaled and Intranasal Drug Product Service Providers: Distribution by Type of Drug Molecule
Table 16.8 Inhaled and Intranasal Drug Product Service Providers: Distribution by Inhaled and Intranasal Drug Product Related Service(s) Offered
Table 16.9 Inhaled and Intranasal Drug Product Service Providers: Distribution by Type of Formulation
Table 16.10 Inhaled and Intranasal Drug Product Service Providers: Distribution by Type of Dosage Form
Table 16.11 Inhaled and Intranasal Drug Product Service Providers: Route of Administration
Table 16.12 Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers: Distribution by Year of Establishment
Table 16.13 Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers: Distribution by Company Size
Table 16.14 Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers: Distribution by Scale of Operation
Table 16.15 Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers: Distribution by Location of Headquarters
Table 16.16 Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers: Distribution by Location of Inhaled and Intranasal Drug Delivery System Manufacturing Facilities
Table 16.17 Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers: Distribution by Inhaled and Intranasal Drug Delivery System Related Service(s) Offered
Table 16.18 Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers: Distribution by Type of Formulation
Table 16.19 Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers: Distribution by Type of Drug Delivery System Used
Table 16.20 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-June 2020
Table 16.21 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.22 Partnerships and Collaborations: Year-wise Trend by Type of Partnership 2015-June 2020
Table 16.23 Partnerships and Collaborations: Distribution by Type of Partnership, 2015-2017 and 2018-June 2020
Table 16.24 Partnerships and Collaborations: Distribution by Scale of Operation
Table 16.25 Partnerships and Collaborations: Distribution by Type of Inhaled and Intranasal Drug Product Related Service(s) Offered
Table 16.26 Partnerships and Collaborations: Distribution Type of Formulation
Table 16.27 Partnerships and Collaborations: Distribution by Type of Drug Delivery System Used
Table 16.28 Most Active Players: Distribution by Number of Partnerships
Table 16.29 Partnerships and Collaborations: Geographical Analysis
Table 16.30 Partnerships and Collaborations: Intercontinental and Intracontinental
Table 16.31 Global Demand for Inhaled and Intranasal Dev Drug Delivery System, 2020-2030 (Million Units)
Table 16.32 Global Demand for Inhaled and Intranasal Drug Delivery System: Distribution by Type of Delivery System (Million Units)
Table 16.33 Global Demand for Inhaled and Intranasal Drug Delivery System: Distribution by Type of Drug Delivery System Used (Million Units)
Table 16.34 Global Demand for Inhaled and Intranasal Drug Delivery System: Distribution by Key Geographical Locations (Million Units)
Table 16.35 Overall Inhaled and Intranasal Drug Product Contract Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Billion)
Table 16.36 Inhaled and Intranasal Drug Product Contract Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Scale of Operation (USD Million)
Table 16.37 Inhaled and Intranasal Drug Product Contract Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Type of Inhaled and Intranasal Drug Product Related Service(s) (USD Million)
Table 16.38 Inhaled and Intranasal Drug Product Contract Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Type of Drug Delivery System Used (USD Million)
Table 16.39 Inhaled and Intranasal Drug Product Contract Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Route of Administration (USD Million)
Table 16.40 Inhaled and Intranasal Drug Product Contract Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Key Geographical Regions (USD Million)
Table 16.41 Inhaled and Intranasal Drug Product Contract Manufacturing Market for Inhalable Formulations, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Type of Disease Indication (USD Million)
Table 16.42 Inhaled and Intranasal Drug Product Contract Manufacturing Market for Nasal Formulations, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Type of Drug Class, 2020-2030 (USD Million)
Table 16.43 Overall Inhaled and Intranasal Drug Delivery System Contract Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Billion)
Table 16.44 Inhaled and Intranasal Drug Delivery System Contract Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Scale of Operation (USD Million)
Table 16.45 Inhaled and Intranasal Drug Delivery System Contract Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Type of Drug Delivery System Used (USD Million)
Table 16.46 Inhaled and Intranasal Drug Delivery System Contract Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Route of Administration (USD Million)
Table 16.47 Inhaled and Intranasal Drug Delivery System Contract Manufacturing Services Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Key Geographical Regions (USD Million)
Table 16.48 Inhaled and Intranasal Product Contract Services Market, 2015-2030: COVID-19 Impact Informed Scenario (USD Billion)

List Of Company

  1. 3M
  2. 3P innovation
  3. Actelion Pharmaceuticals
  4. Aerami Therapeutics (formerly Dance Biopharm)
  5. Aerosol Research and Engineering Laboratories
  6. Akums Drugs & Pharmaceuticals
  7. Alcami
  8. Alpic Biotech
  9. Altaris Capital Partners
  10. Altimmune 
  11. Amneal Pharmaceuticals
  12. Aptar Pharma
  13. Arch Biopartners
  14. Arcturus Therapeutics
  15. ASM Aerosol-Service
  16. Aspen Pharmacare
  17. AstraZeneca
  18. Atossa Therapeutics
  19. Aurohealth
  20. Basic Pharma
  21. Battelle
  22. Bespak
  23. Beximco Pharmaceuticals
  24. BioCare Group
  25. Biofilms Research Center for Biointerfaces, Malmö University
  26. Boehringer Ingelheim
  27. Breath Therapeutics
  28. Capsugel
  29. Carclo Technical Plastics
  30. Catalent
  31. CF PharmTech
  32. Charles River Laboratories
  33. Chemic Laboratories
  34. Chiesi Farmaceutici
  35. Chromcore Lifesciences
  36. Cirrus Pharmaceuticals 
  37. COC Farmaceutici
  38. Colep
  39. Confab
  40. Consort Medical
  41. Contract Pharmaceuticals
  42. Creative Biolabs
  43. Circassia
  44. CrystecPharma
  45. Curida
  46. CytoAgents 
  47. Dalton Pharma Services
  48. DFE Pharma
  49. Doctor Pack
  50. Dorizoe Lifesciences
  51. DPT Laboratories
  52. Dr. Reddy’s Laboratories
  53. DRK Pharma Solutions
  54. Dwarkesh Pharmaceuticals
  55. EKG Life Science Solutions
  56. Elfin Drugs
  57. Emmace Consulting
  58. Ennaid Therapeutics
  59. Ethris
  60. Eurofins
  61. Evoke Pharma
  62. Evonik
  63. Experic
  64. Farbe Firma
  65. FAMAR
  66. Focus Inhalation
  67. Forefront Medical Technology
  68. Forest Laboratories
  69. Genentech
  70. Gerresheimer
  71. Getron Pharmaceuticals
  72. Gilead Sciences
  73. GlaxoSmithKline
  74. Global Pharma
  75. Hikma Pharmaceuticals
  76. Horizon Pharmaceuticals 
  77. Hovione
  78. Humanigen 
  79. Iconovo
  80. IIT Research Institute (IITRI)
  81. Impopharma
  82. Importfab
  83. Inhalexpert
  84. InhaTarget Therapeutics
  85. Insmed
  86. Intas Pharmaceuticals
  87. Intertek
  88. Invion
  89. iPharma
  90. ITC Farma
  91. J Pharmaceuticals
  92. Jabil
  93. Jagotec
  94. Janssen Pharmaceuticals
  95. Johnson & Johnson
  96. Kiel University
  97. Kindeva Drug Delivery
  98. King’s College London
  99. Kymos Pharma Services
  100. Labiana Pharmaceuticals
  101. Lamda Laboratories
  102. Lannet Technologies
  103. LEAX Group
  104. Lepharm
  105. Life Vision Healthcare
  106. Lindal Group
  107. Liquidia Technologies
  108. Lomapharm
  109. Lonza
  110. Lovelace Biomedical
  111. Lxir Medilabs (A unit of SMM Life Sciences)
  112. M2M Pharmaceuticals
  113. Macter International
  114. Malmö University
  115. MannKind
  116. Mapaex
  117. Maya Biotech
  118. McMaster University
  119. Medicair Bioscience Laboratories
  120. Medicilon
  121. Medlab Pharmaceuticals
  122. MedPharm
  123. Menarini Group
  124. Merck
  125. Micro-Sphere
  126. MidasCare
  127. Mipharm
  128. MMG Healthcare
  129. Moderna Therapeutics
  130. Molex
  131. Medicon Valley Inhalation Consortium (MVIC)
  132. Mylan
  133. Nanologica
  134. Nanopharm
  135. Napp Pharmaceuticals
  136. Nelipak Healthcare Packaging
  137. Nelson Laboratories
  138. Nemera
  139. Nephron Pharmaceuticals
  140. Neurelis
  141. Neurimmune
  142. Newtec Pro Manufacturing
  143. Next Breath
  144. Nipro
  145. Nitto Medic
  146. Nivon Specialties
  147. Noble
  148. Novartis
  149. One Pharma
  150. Orion
  151. Oté Pharma
  152. Optinose
  153. Paragon Nordic
  154. PARI Pharma
  155. PCI Pharma Services
  156. Penta Arzneimittel
  157. Pfizer
  158. Pharma Stulln
  159. Pharma Tech
  160. PharmaCielo
  161. Pharmaserve
  162. Pharmaterials
  163. PHAST (Acquired by Eurofins)
  164. Phillips-Medisize
  165. Pine Lake Laboratories
  166. Polyphor
  167. PPD Laboratories
  168. Probiotec
  169. Propeller Health
  170. Proveris Scientific
  171. Pulmatrix
  172. PulmoFlow
  173. Pursuit Pharma
  174. Pushkar Pharma
  175. Quotient Sciences
  176. Recipharm
  177. Renaissance Pharmaceuticals
  178. Roche
  179. Rommelag
  180. Rubicon Research
  181. S.R.Chemicals and Pharmaceuticals
  182. SAFE Pharmaceutical
  183. Salvat
  184. Sandoz
  185. Sanofi
  186. Sciarra Laboratories
  187. Seikagaku
  188. Sentiss Pharma
  189. Servier Pharmaceuticals
  190. SHL Group
  191. Simpler Consulting
  192. SkyePharma
  193. Smithers
  194. Spicona 
  195. Stabicon Life Sciences
  196. Stevanato Group
  197. Summit Biosciences
  198. Sunovion
  199. Sunovion Pharmaceuticals
  200. Synerlab
  201. Takeda
  202. Teva Pharmaceuticals
  203. The Indian Pharmaceutical Association
  204. The Ritedose Corporation
  205. Theravance Biopharma 
  206. Tinuum
  207. Toxikon
  208. Trillium Health Care Products
  209. UCB Pharma
  210. Ultratech India
  211. United Therapeutics
  212. University of Birmingham 
  213. University of Copenhagen
  214. University of Cyprus
  215. University of Florida
  216. University of Turku
  217. Bausch Health (formerly Valeant Pharmaceuticals)
  218. Vectura
  219. ViralClear Pharmaceuticals (A subsidiary of BioSig Technologies)
  220. Vinventions
  221. Vivimed
  222. West Coast Pharmaceutical
  223. Westmed Medical Group

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com